Biotech Co.**

Pharma Co. (Symbol/Country)

Type/Product Area

Amount

Terms/Details (Date)

Aurora Biosciences Inc.

Pfizer Inc. (NYSE:PFE)

Technology access agreement; Aurora will provide automated systems (including those for compound storage, high-throughput screening and multiple ion channel lead discovery platforms) at Pfizer research facilities worldwide

$50M

Contract includes $50M in guaranteed payments, plus milestones, profit-sharing for commercialized compounds identified using the system, and funding related to the exercise of various options included in the deal (6/99)

Centocor Inc.

Covance (NYSE:CVD

Long-term manufacturing agreement under which Covance will produce Centocor's Retavase for the U.S. and Canadian markets

ND

ND (4/99)

Cephalon Inc.

Abbott Laboratories (NYSE:ABT)

Collaborative agreement to further develop and market Abbott's Gabitril, an anti-epileptic drug, in the U.S.; Abbott gains a right of first negotiation to develop and promote Cephalon's Provigil (an FDA-approved narcolepsy drug) should Cephalon elect to collaborate with a 3rd party in the U.S.

ND

Cephalon is required to make certain promotional and clinical development expenditures, and will share in growth of the product sales beyond a contractually specified baseline; Abbott has a right of first negotiation to develop and pro-mote Cephalon's Provigilin the U.S. (6/99)

H. Lundbeck A/S (Denmark)

Development and marketing agreement for Cephalon's preclinical-stage receptor tyrosine kinase inhibitors

$40M

Cephalon will receive aprox-imately $40M, which includesan up-front license fee, research and milestone payments, and an equity investment of $12M (1M Cephalon shares at $12 each); Lundbeck will also share development costs and support research; Lundbeck gains commercial rights in Europe and certain other territories (6/99)

Cypress Bioscience Inc.

Fresenius AG (Germany)

Fresenius exercised option to acquire manufacturing rights for Cypress' Prosorba column for treating rheumatoid arthritis

$5.2M

Fresenius gained the option as part of marketing alliance signed 3/99; the $4M Cypress had drawn down from a line of credit will be applied to the purchase price of the facility, and Fresenius paid an additional $1.2M to exercise the purchase option (4/99)

DiagnoCure Inc.(Canada;MSE:CUR)

Medite Histotechnic Italia (Italy)

Distribution agreement under which Medite will distribute in Italy DiagnoCure's ImmunoCyt diagnostic test for the detection of superficial bladder cancer using monoclonal antibodies

ND

ND (3/99)

Euro-Diagnostica AB (Sweden)

Distribution agreement under which Euro-Diagnostica will distribute ImmunoCyt's monoclonal antibody-based diagnostic test for superficial bladder cancer in Sweden, Norway, Denmark and Finland

ND

ND (5/99)

Digene Corp.

Abbott Laboratories (NYSE:ABT)

Sales and marketing agreement under which Abbott will handle those responsibilities for Digene's women's health and blood virus DNA testing products in Europe, the Middle East and Africa; agreement replaces Digene's agreement with International Murex Technologies Corp., which Abbott acquired in 1998-

ND

ND (5/11)

Draxis Health Inc. (Canada)

Elan Corp. plc (Ireland)

Draxis licensed from Elan exclusive Canadian rights to 8 neurology products, of which 3 are approved, 3 are nearing approval and 2 are late-stage; products include Zanaflex (tizanidine hydrochloride; approved); Diastat (diazepam rectal gel; approved), Mysoline (primidone; approved), frovatriptan, NeuroBloc (botulinum toxin type B), ziconotide, Zonegran (zonisamide) and Zelapar (selegiline hydrochloride flashtab)

Elan to receive $12M, but will purchase $8M in Draxis equity

Draxis will pay Elan a 1-time up-front fee of $12M; Elan will purchase 3.04M treasury shares of Draxis at a price per share of $2.63 ($8M total), a premium to trading price, representing a stake of 8.6%; Everen Securities acted as financial advisor to Draxis; Elan will supply manufactured products to Draxis and provide assistance with pricing and regulatory and launch activities; agreement expires 12/31/98 (6/99)

Epitope Inc.

Organon Teknika Ltd. (subsidiary of Akzo Nobel; the Netherlands)

Organon will collaborate on final development of OraQuick (an oral fluid rapid assay test for HIV infection) and will manufacture initial pre-production lots

ND

If product succeeds in winning approvals, companies plan to negotiate a long-term manufacturing and supply agreement (4/99)

IDEC Pharmaceuticals Inc.

Schering AG (Germany)

Marketing and distribution agreement for IDEC's Zevalin (Ibritumomab Tiuxetan; formerly called IDEC Y2B8), an anticancer monoclonal antibody conjugated to yttrium-90; product is in development as therapy for low-grade and/or follicular non-Hodgkin's B-cell lymphoma

$47.5M

Schering will pay IDEC $13M as an up-front licensing fee and will provide $15M in committed funding for Zevalin; IDEC may receive up to $19.5M in additional milestones, plus a royalty on sales outside the U.S.; Schering gains exclusive marketing rights outside the U.S.; IDEC retains U.S. rights (6/99)

Maxim Pharmaceuticals Inc.

F.H. Faulding & Co. Ltd. (Australia)

Marketing agreement for Maxim's Maxamine anti-cancer therapy in Australia and New Zealand

ND

Faulding will pay marketing rights fees and milestones, and provide clinical and regulatory assistance; Faulding will assume responsibility for registration and marketing approval and related applications for reimbursment in Australia and New Zealand; combined with agreement for Israel (see below), Maxim expects to receive a 40% or greater share of Maxamine sales with in these territories (5/99)

MegaPharm Ltd. (Israel)

Marketing agreement for Maxim's Maxamine anti-cancer therapy in Israel

ND

As part of the agreement, MegaPharm will manage the Israeli component of 3 clinical trials and also will assume responsibility for approval application in Israel; combined with agreement for Australia and New Zealand (see above), Maxim expects to receive a 40% or greater share of Maxamine sales within these territories (5/99)

Palatin Technologies

Mallinckrodt Inc. (NYSE:MKG)

Worldwide marketing agreement (excluding Europe) for Palatin's LeuTech radiolabeled infection imaging agent

$23M ($13M equity purchase)

Mallinckrodt gains exclusive worldwide license (excluding Europe) for sales, marketing and distribution of LeuTech products; Palatin will receive milestone payments, funding for 50% of development and clinical testing expenses for all indications covered in the agreement, a transfer price for LeuTech sales to Mallinckrodt and a royalty on sales; Malllinckrodt will purchase $13M worth of restricted, unregistered convertible preferred shares, which are convertible after 5 years to 0.7M common shares; milestones include $5M upon FDA marketing clearance and $5M when Mallinckrodt's LeuTech sales reach $20M (5/99)

PathoGenesis Corp.

Swedish Orphan AB

Distribution agreement for PathoGenesis' TOBI (tobra-mycin solution for inhalation) in Sweden, Denmark, Norway and Finland; drug is currently under review in the U.K., the lead country for seeking approval in the European Union

ND

ND (5/99)

PulmoPharm (Germany)

PulmoPharm will market PathoGenesis' TOBI (tobra- mycin for inhalation) for cystic fibrosis in Germany upon the drug's approval

ND

PathoGenesis purchased equity amounting to 20 percent of PulmoPharm at an undisclosed price (5/99)

SangStat Medical Corp.

Abbott Laboratories (NYSE:ABT)

Co-promotion, distribution and research agreement for SangStat's SangCya (cyclo-sporine oral solution; FDA-approved) in the U.S.

$14M (equity purchase)

Partnership marks continuation of initial agreement for Abbott to provide bulk cyclosporine to SangStat; Abbott will make a $14M equity purchase in SangStat, make up-front and milestone payments, and will make a long-term loan to SangStat (5/99)

SciClone Pharmaceuticals

Sigma-Tau SpA (Italy)

Sigma-Tau will market SciClone's Zadaxin thymosin alpha 1 for treatment of cancer and hepatitis in Italy, Spain and Switzerland

ND

Sigma-Tau receives semi-exclusive development and marketing rights in Italy and Spain, and exclusive rights in Switzerland; Sigma-Tau will be responsible for clinical development and regulatory submissions in Italy (4/99)

Triangle Pharmaceuticals Inc.

Abbott Laboratories (NYSE:ABT)

Marketing agreement for 6 antiviral products, 4 from Triangle and 2 from Abbott; Triangle products are Coviracil (for HIV and hepatitis B virus), Coactinon (formerly MKC-442; for HIV), DAPD (for HIV) and L-FMAU (for HBV)

$335M ($118M equity)

In the U.S., Abbott and Triangle will co-promote 4 Triangle products currently in development for HIV and hepatitis B virus, and Abbott's 2 HIV protease inhibitors (Norvir, which is FDA-approved, and Phase III-stage ABT-378); outside the U.S., Abbott will have exclusive sales and marketing rights for the 4 Triangle antivirals; Abbott will purchase 6.57M shares of >Triangle stock at $18 per share, for a total of $118M; additionally, Abbott will provide research funding of $31.7M and up to $185M in milestones, plus will share future commercialization costs; companies will share profits and losses for all Triangle drug candidates, and Triangle will receive detailing fees and commissions on incremental sales generated for the Abbott products; Abbott will have right of 1st discussion on future Triangle compounds, and the partners plan to execute a manufacturing agreement to allow Abbott to produce certain Triangle products worldwide; Warburg Dillon Read acted as financial adviser to Triangle, and Goldman Sachs advised Abbott (6/99)

Vivus Inc.

Bio-Medic Institute Inc. (Japan)

Agreement for registration and commercialization of Vivus' Muse (alprostadil; for erectile dysfunction) in Japan

$5M

Bio-Medic will make a $5M up-front payment to Vivus and assume responsibility for all clinical and regulatory activities necessary for registration of Muse in Japan; Vivus will manufacture and sell Muse to Bio-Medic (5/99)

NOTES:

# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 4/1/99 and 6/30/99.

ND = Not disclosed, reported and/or available; NYSE=New York Stock Exchange; ASX=Australian Stock Exchange

* Private companies are indicated with an asterisk.

** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 14 - 15.